Optimal glucose control and diabetes medication like glucagon‐like peptide‐1 receptor agonists have shown beneficial effects on prevention of limb amputation,62, 63 whereas sodium glucose cotransporter 2 inhibitors are suspected of increasing the risk for amputation in PAD patients.64, 65. Here, SLC5A2 is linked to peripheral arterial disease.